Sponsors: []Modifications: Overdose Response(1)  "Controlled substance" means the same as that term is defined in Title 58, Chapter37, Utah Controlled Substances Act.(2)(3),,,(4)  "Increased risk" means risk exceeding the risk typically experienced by anindividual who is not using, and is not likely to use, an opiate.(5)means the samethat term is(6):(a)an opiate-relatedevent; and(b)  includes paraphernalia required to administer the drug.(7)(i)  For purposes of Subsection (1)(a)(ii), "a person other than a health carefacility or health care provider" includes a person described in Subsections 26-55-105(1)(a)(i)through (1)(a)(iv).(ii)an individualexperiencingfor(i)  to(ii)  to, including a person describedin Subsections 26-55-105(1)(a)(i) through (1)(a)(iv),is;(b)  without a prescriber-patient relationship; and(c)  without liability for any civil damages for acts or omissions made as a result ofprescribing or dispensing the opiate antagonist in good faith.health care providerto an individual under Subsection (2)(a)instruction:(a)  on the proper administration of the opiate antagonist; and(b)  that the individual to whom the opiate antagonist is dispensed should ensure thatthe individual to whomis administered is takenimmediately following administration of the opiate antagonist     26-55-105.(1)  For purposes of this section, "persons who may be in a position to assist anindividual who is at increased risk of experiencing an opiate-related drug overdose event":(a)  means the following organizations:(i)  a law enforcement agency;(ii)  an organization that provides drug or alcohol treatment services;(iii)  an organization that provides services to the homeless;(iv)  an organization that provides training on the proper administration of an opiateantagonist in response to an opiate-related drug overdose event; or(v)  except as provided in Subsection (1)(b), any other organization, as defined bydepartment rule made under Subsection (7)(e), that may be in a position to assist an individualwho is at increased risk of experiencing an opiate-related drug overdose event; and(b)  does not mean:(i)  a person licensed under Title 58, Chapter 17b, Pharmacy Practice Act;(ii)  a health care facility; or(iii)  an individual.(2)  There is created within the department the "Opiate Overdose Outreach PilotProgram."(3)  No later than September 1, 2016, and with available funding, the department shallgrant funds through the program to persons who may be in a position to assist an individualwho is at increased risk of experiencing an opiate-related drug overdose event.(4)  Funds granted by the program:(a)  may be used by a grantee to:(i)  pay for the purchase by the grantee of an opiate antagonist; or(ii)  pay for the grantee's cost of providing training on the proper administration of anopiate antagonist in response to an opiate-related drug overdose event; and(b)  may not be used:(i)  to pay for costs associated with the storage or dispensing of an opiate antagonist; or(ii)  for any other purposes.(5)  Grantees shall report annually to the department on the use of granted funds inaccordance with department rules made under Subsection (7)(d).(6)  The department may not use funds appropriated to it for the program to pay forcosts associated with administering the program.(7)  No later than July 1, 2016, the department shall, in accordance with Title 63G,Chapter 3, Utah Administrative Rulemaking Act, make rules specifying:(a)  how to apply for a grant from the program;(b)  the criteria used by the department to determine whether a grant request isapproved, including criteria providing that:(i)  grants are awarded to areas of the state, including rural areas, that would benefitmost from the grant; and(ii)  no more than 15% of the total amount granted by the program is used to pay forgrantees' costs of providing training on the proper administration of an opiate antagonist inresponse to an opiate-related drug overdose event;(c)  the criteria used by the department to determine the amount of a grant;(d)  the information a grantee shall report annually to the department under Subsection(4), including:(i)  the amount of opiate antagonist purchased and dispensed by the grantee during thereporting period;(ii)  the names of the individuals to whom the opiate antagonist was dispensed by thegrantee;(iii)  the number of lives known to have been saved during the reporting period as aresult of opiate antagonist dispensed by the grantee; and(iv)  the manner in which the grantee shall record, preserve, and make available foraudit by the department the information described in Subsections (7)(d)(i) through (7)(d)(iii);and(e)  as required by Subsection (1)(a)(v), any other organization that may be in a positionto assist an individual who is at increased risk of experiencing an opiate-related drug overdoseevent.(8)  The department shall report to the Legislature's Social Services AppropriationsSubcommittee no later than September 1 of each year on the outcomes of the Opiate OverdoseOutreach Pilot Program.(1)  As used in this section:(a)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.(b)  "Opiate-related drug overdose event" means the same as that term is defined inSection 26-55-102.(2)an individualindividualexperiencingevent(3)and Title 26, Chapter 55, Opiate OverdoseResponse Act,(4), including a person described inSubsections 26-55-105(1)(a)(i) through (1)(a)(iv),an individual(1)  As used in this section:(a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.(b)  "Increased risk" means the same as that term is defined in Section 26-55-102.(c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.(d)  "Opiate-related drug overdose event" means the same as that term is defined inSection 26-55-102.(e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.an individual, including a person described inSubsections 26-55-105(1)(a)(i) through (1)(a)(iv),anindividualisOverdose Response(1)  As used in this section:(a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.(b)  "Increased risk" means the same as that term is defined in Section 26-55-102.(c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.(d)  "Opiate-related drug overdose event" means the same as that term is defined inSection 26-55-102.(e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.an individual, including a person described inSubsections 26-55-105(1)(a)(i) through (1)(a)(iv),anindividualisOverdose Response(1)  As used in this section:(a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.(b)  "Increased risk" means the same as that term is defined in Section 26-55-102.(c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.(d)  "Opiate-related drug overdose event" means the same as that term is defined inSection 26-55-102.(e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.an individual, including a person described inSubsections 26-55-105(1)(a)(i) through (1)(a)(iv),anindividualisOverdose Response(1)  As used in this section:(a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.(b)  "Increased risk" means the same as that term is defined in Section 26-55-102.(c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.(d)  "Opiate-related drug overdose event" means the same as that term is defined inSection 26-55-102.(e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.an individual, including a person described inSubsections 26-55-105(1)(a)(i) through (1)(a)(iv),anindividualisOverdose Response(14)  The Opiate Overdose Outreach Pilot Program created in Section 26-55-105.Under the terms and conditions of Title 63J, Chapter 1, Budgetary Procedures Act, forthe fiscal year beginning July 1, 2016, and ending June 30, 2017, the following sums of moneyare appropriated from resources not otherwise appropriated, or reduced from amountspreviously appropriated, out of the funds or amounts indicated.  These sums of money are inaddition to amounts previously appropriated for fiscal year 2017.Item 1.  To Department of Health - Disease Control and PreventionFrom General Fund$500,000337                    Schedule of Programs:338                    Opiate Overdose Outreach Pilot Program          $500,000339          Item 2.  To Department of Health - Disease Control and Prevention340               From General Fund, One-time$500,000341                    Schedule of Programs:342                    Opiate Overdose Outreach Pilot Program          $500,000Legislative Review NoteOffice of Legislative Research and General Counsel
Schedule of Programs:Opiate Overdose Outreach Pilot Program          $500,000Item 2.  To Department of Health - Disease Control and PreventionFrom General Fund, One-time$500,000341                    Schedule of Programs:342                    Opiate Overdose Outreach Pilot Program          $500,000Legislative Review NoteOffice of Legislative Research and General Counsel
Schedule of Programs:Opiate Overdose Outreach Pilot Program          $500,000Full text:



1     OPIATE OVERDOSE RESPONSE ACT -- PILOT PROGRAM2     AND OTHER AMENDMENTS3     2016 GENERAL SESSION4     STATE OF UTAH5     Chief Sponsor:  Mike K. McKell6     Senate Sponsor:  ____________7      8     LONG TITLE9     General Description:10          This bill renames the Emergency Administration of Opiate Antagonist Act as the11     Opiate Overdose Response Act, amends the act, and makes related amendments.12     Highlighted Provisions:13          This bill:14                renames the Emergency Administration of Opiate Antagonist Act as the Opiate15     Overdose Response Act;16                amends definitions;17                amends liability provisions; 18                creates the Opiate Overdose Outreach Pilot Program within the Department of19     Health;20                authorizes grants from the program;21                specifies how grants may be used;22                requires annual reporting by grantees;23                requires rulemaking by the Department of Health;24                requires annual reporting on the program by the Department of Health;25                designates program funding as nonlapsing; and26                makes technical changes. 27     Money Appropriated in this Bill:28          This bill appropriates:29                to Department of Health -- Disease Control and Prevention, as an ongoing30     appropriation:31                     from the General Fund, $500,000, for the newly created Opiate Overdose32     Outreach Pilot Program;  and33                to Department of Health -- Disease Control and Prevention , as a one-time34     appropriation:35                     from the General Fund, $500,000, for the newly created Opiate Overdose36     Outreach Pilot Program. 37     Other Special Clauses:38          None39     Utah Code Sections Affected:40     AMENDS:41          26-55-101, as enacted by Laws of Utah 2014, Chapter 13042          26-55-102, as enacted by Laws of Utah 2014, Chapter 13043          26-55-104, as enacted by Laws of Utah 2014, Chapter 13044          58-17b-507, as enacted by Laws of Utah 2014, Chapter 13045          58-31b-703, as enacted by Laws of Utah 2014, Chapter 13046          58-67-702, as enacted by Laws of Utah 2014, Chapter 13047          58-68-702, as enacted by Laws of Utah 2014, Chapter 13048          58-70a-505, as enacted by Laws of Utah 2014, Chapter 13049          63J-1-602.1, as last amended by Laws of Utah 2015, Chapters 136 and 18050     ENACTS:51          26-55-105, Utah Code Annotated 195352      53     Be it enacted by the Legislature of the state of Utah:54          Section 1.  Section 26-55-101 is amended to read:55     CHAPTER 55.  OPIATE OVERDOSE RESPONSE ACT56          26-55-101. Title.57          This chapter is known as the "[Emergency Administration of] Opiate [Antagonist]58     Overdose Response Act."59          Section 2.  Section 26-55-102 is amended to read:60          26-55-102. Definitions.61          As used in this chapter:62          (1)  "Controlled substance" means the same as that term is defined in Title 58, Chapter63     37, Utah Controlled Substances Act.64          [(1)] (2)  "Health care facility" means a hospital, a hospice inpatient residence, a65     nursing facility, a dialysis treatment facility, an assisted living residence, an entity that provides66     home- and community-based services, a hospice or home health care agency, or another facility67     that provides or contracts to provide health care services, which facility is licensed under68     Chapter 21, Health Care Facility Licensing and Inspection Act.69          [(2)] (3)  "Health care provider" means:70          (a)  a physician, as defined in Section 58-67-102;71          (b)  an advanced practice registered nurse, as defined in Subsection 58-31b-102(13); or72          (c)  a physician assistant, as defined in Section 58-70a-102.73          (4)  "Increased risk" means risk exceeding the risk typically experienced by an74     individual who is not using, and is not likely to use, an opiate.75          [(3)] (5)  "Opiate" [is] means the same as that term is defined in Section 58-37-2.76          [(4)] (6)  "Opiate antagonist":77          (a)  means naloxone hydrochloride or any similarly acting drug that is not a controlled78     substance and that is approved by the federal Food and Drug Administration for the treatment79     of [a] an opiate-related drug overdose[.] event; and80          (b)  includes paraphernalia required to administer the drug.81          [(5)] (7)  "Opiate-related drug overdose event" means an acute condition, including a82     decreased level of consciousness or respiratory depression resulting from the consumption or83     use of a controlled substance, or another substance with which a controlled substance was84     combined, and that a person would reasonably believe to require medical assistance.85          Section 3.  Section 26-55-104 is amended to read:86          26-55-104. Prescribing, dispensing, and administering an opiate antagonist --87     Immunity from liability.88          (1) (a) (i)  For purposes of Subsection (1)(a)(ii), "a person other than a health care89     facility or health care provider" includes a person described in Subsections 26-55-105(1)(a)(i)90     through (1)(a)(iv).91          (ii)  Except as provided in Subsection (1)(b), a person other than a health care facility or92     health care provider who acts in good faith to administer an opiate antagonist to [another93     person] an individual whom the person believes to be [suffering] experiencing an opiate-related94     drug overdose event is not liable for any civil damages [or] for acts or omissions made as a95     result of administering the opiate antagonist.96          (b)  A health care provider:97          (i)  does not have immunity from liability under Subsection (1)(a) when the health care98     provider is acting within the scope of the health care provider's responsibilities or duty of care;99     and100          (ii)  does have immunity from liability under Subsection (1)(a) if the health care101     provider is under no legal duty to respond and otherwise complies with Subsection (1)(a).102          (2)  Notwithstanding Sections 58-1-501, 58-17b-501, and 58-17b-502, a health care103     provider who is licensed to prescribe [or dispense] an opiate antagonist may[, without a104     prescriber-patient relationship,] prescribe or dispense an opiate antagonist [without liability for105     any civil damages or acts or omissions made as a result of prescribing or dispensing an opiate106     antagonist in good faith, to]:107          (a) (i)  to an individual who is at increased risk of experiencing [or who is likely to108     experience] an opiate-related drug overdose event; or109          [(b)] (ii)  to a family member of, friend of, or other person, including a person described110     in Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), who [may be] is in a position to assist an111     individual who may be at increased risk of experiencing [or who is likely to experience] an112     opiate-related drug overdose event[.];113          (b)  without a prescriber-patient relationship; and114          (c)  without liability for any civil damages for acts or omissions made as a result of115     prescribing or dispensing the opiate antagonist in good faith.116          (3)  A [person] health care provider who [prescribes or] dispenses an opiate antagonist117     to an individual under Subsection (2)(a) shall provide education to the individual [described in118     Subsection (2)(a) or (b)] that includes [instructions to take the person who received]119     instruction:120          (a)  on the proper administration of the opiate antagonist; and121          (b)  that the individual to whom the opiate antagonist is dispensed should ensure that122     the individual to whom the opiate antagonist is administered is taken to an emergency care123     facility for a medical evaluation immediately following administration of the opiate antagonist.124          Section 4.  Section 26-55-105 is enacted to read:125          26-55-105. Opiate Overdose Outreach Pilot Program -- Grants -- Annual126     reporting by grantees -- Rulemaking -- Annual reporting by department.127          (1)  For purposes of this section, "persons who may be in a position to assist an128     individual who is at increased risk of experiencing an opiate-related drug overdose event":129          (a)  means the following organizations:130          (i)  a law enforcement agency;131          (ii)  an organization that provides drug or alcohol treatment services;132          (iii)  an organization that provides services to the homeless;133          (iv)  an organization that provides training on the proper administration of an opiate134     antagonist in response to an opiate-related drug overdose event; or135          (v)  except as provided in Subsection (1)(b), any other organization, as defined by136     department rule made under Subsection (7)(e), that may be in a position to assist an individual137     who is at increased risk of experiencing an opiate-related drug overdose event; and138          (b)  does not mean:139          (i)  a person licensed under Title 58, Chapter 17b, Pharmacy Practice Act;140          (ii)  a health care facility; or141          (iii)  an individual.142          (2)  There is created within the department the "Opiate Overdose Outreach Pilot143     Program."144          (3)  No later than September 1, 2016, and with available funding, the department shall145     grant funds through the program to persons who may be in a position to assist an individual146     who is at increased risk of experiencing an opiate-related drug overdose event.147          (4)  Funds granted by the program:148          (a)  may be used by a grantee to:149          (i)  pay for the purchase by the grantee of an opiate antagonist; or150          (ii)  pay for the grantee's cost of providing training on the proper administration of an151     opiate antagonist in response to an opiate-related drug overdose event; and152          (b)  may not be used:153          (i)  to pay for costs associated with the storage or dispensing of an opiate antagonist; or154          (ii)  for any other purposes.155          (5)  Grantees shall report annually to the department on the use of granted funds in156     accordance with department rules made under Subsection (7)(d).157          (6)  The department may not use funds appropriated to it for the program to pay for158     costs associated with administering the program.159          (7)  No later than July 1, 2016, the department shall, in accordance with Title 63G,160     Chapter 3, Utah Administrative Rulemaking Act, make rules specifying:161          (a)  how to apply for a grant from the program;162          (b)  the criteria used by the department to determine whether a grant request is163     approved, including criteria providing that:164          (i)  grants are awarded to areas of the state, including rural areas, that would benefit165     most from the grant; and166          (ii)  no more than 15% of the total amount granted by the program is used to pay for167     grantees' costs of providing training on the proper administration of an opiate antagonist in168     response to an opiate-related drug overdose event;169          (c)  the criteria used by the department to determine the amount of a grant;170          (d)  the information a grantee shall report annually to the department under Subsection171     (4), including:172          (i)  the amount of opiate antagonist purchased and dispensed by the grantee during the173     reporting period;174          (ii)  the names of the individuals to whom the opiate antagonist was dispensed by the175     grantee;176          (iii)  the number of lives known to have been saved during the reporting period as a177     result of opiate antagonist dispensed by the grantee; and178          (iv)  the manner in which the grantee shall record, preserve, and make available for179     audit by the department the information described in Subsections (7)(d)(i) through (7)(d)(iii);180     and181          (e)  as required by Subsection (1)(a)(v), any other organization that may be in a position182     to assist an individual who is at increased risk of experiencing an opiate-related drug overdose183     event.184          (8)  The department shall report to the Legislature's Social Services Appropriations185     Subcommittee no later than September 1 of each year on the outcomes of the Opiate Overdose186     Outreach Pilot Program.187          Section 5.  Section 58-17b-507 is amended to read:188          58-17b-507. Opiate antagonist -- Immunity from liability -- Exclusion from189     unlawful or unprofessional conduct.190          (1)  As used in this section:191          (a)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.192          (b)  "Opiate-related drug overdose event" means the same as that term is defined in193     Section 26-55-102.194          [(1)] (2)  A person licensed under this chapter who dispenses an opiate antagonist [as195     defined in Section 26-55-102] to an individual with a prescription for an opiate antagonist is196     not liable for any civil damages resulting from the outcomes that result from the eventual197     administration of the opiate antagonist to [a person] an individual who another [person]198     individual believes is [suffering] experiencing an opiate-related drug overdose [as defined in199     Section 26-55-102] event.200          [(2)] (3)  The provisions of this section and Title 26, Chapter 55, Opiate Overdose201     Response Act, do not establish a duty or standard of care in the prescribing, dispensing, or202     administration of an opiate antagonist.203          [(3)] (4)  It is not unprofessional conduct or unlawful conduct for a licensee under this204     chapter to dispense an opiate antagonist to a person, including a person described in205     Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), on behalf of [another person] an individual if206     the person obtaining the opiate antagonist has a prescription for the opiate antagonist from a207     licensed prescriber.208          Section 6.  Section 58-31b-703 is amended to read:209          58-31b-703. Opiate antagonist -- Exclusion from unprofessional or unlawful210     conduct.211          [(1)  Title 26, Chapter 55, Emergency Administration of Opiate Antagonist Act, applies212     to a licensee under this chapter.]213          (1)  As used in this section:214          (a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.215          (b)  "Increased risk" means the same as that term is defined in Section 26-55-102.216          (c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.217          (d)  "Opiate-related drug overdose event" means the same as that term is defined in218     Section 26-55-102.219          (e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.220          (2)  The prescribing or dispensing of an opiate antagonist [as defined in Section221     26-55-102] by a licensee under this chapter is not unprofessional or unlawful conduct if the222     licensee prescribed or dispensed the opiate antagonist in a good faith effort to assist:223          (a)  [a person] an individual who is at increased risk of experiencing [or who is likely to224     experience] an opiate-related drug overdose event [as defined in Section 26-55-102]; or225          (b)  a family member of, friend of, or other person, including a person described in226     Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), who is in a position to assist [a person] an227     individual who [may be] is at increased risk of experiencing [or who is likely to experience] an228     opiate-related drug overdose event.229          (3)  The provisions of this section and Title 26, Chapter 55, [Emergency Administration230     of] Opiate [Antagonist] Overdose Response Act, do not establish a duty or standard of care in231     the prescribing, dispensing, or administration of an opiate antagonist.232          Section 7.  Section 58-67-702 is amended to read:233          58-67-702. Opiate antagonist -- Exclusion from unlawful or unprofessional234     conduct.235          [(1)  Title 26, Chapter 55, Emergency Administration of Opiate Antagonist Act, applies236     to a licensee under this chapter.]237          (1)  As used in this section:238          (a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.239          (b)  "Increased risk" means the same as that term is defined in Section 26-55-102.240          (c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.241          (d)  "Opiate-related drug overdose event" means the same as that term is defined in242     Section 26-55-102.243          (e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.244          (2)  The prescribing or dispensing of an opiate antagonist [as defined in Section245     26-55-102] by a licensee under this chapter is not unprofessional or unlawful conduct if the246     licensee prescribed or dispensed the opiate antagonist in a good faith effort to assist:247          (a)  [a person] an individual who is at increased risk of experiencing [or who is likely to248     experience] an opiate-related drug overdose event [as defined in Section 26-55-102]; or249          (b)  a family member of, friend of, or other person, including a person described in250     Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), who is in a position to assist [a person] an251     individual who [may be] is at increased risk of experiencing [or who is likely to experience] an252     opiate-related drug overdose event.253          (3)  The provisions of this section and Title 26, Chapter 55, [Emergency Administration254     of] Opiate [Antagonist] Overdose Response Act, do not establish a duty or standard of care in255     the prescribing, dispensing, or administration of an opiate antagonist.256          Section 8.  Section 58-68-702 is amended to read:257          58-68-702. Opiate antagonist -- Exclusion from unlawful or unprofessional258     conduct.259          [(1)  Title 26, Chapter 55, Emergency Administration of Opiate Antagonist Act, applies260     to a licensee under this chapter.]261          (1)  As used in this section:262          (a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.263          (b)  "Increased risk" means the same as that term is defined in Section 26-55-102.264          (c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.265          (d)  "Opiate-related drug overdose event" means the same as that term is defined in266     Section 26-55-102.267          (e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.268          (2)  The prescribing or dispensing of an opiate antagonist [as defined in Section269     26-55-102] by a licensee under this chapter is not unprofessional or unlawful conduct if the270     licensee prescribed or dispensed the opiate antagonist in a good faith effort to assist:271          (a)  [a person] an individual who is at increased risk of experiencing [or who is likely to272     experience] an opiate-related drug overdose event [as defined in Section 26-55-102]; or273          (b)  a family member of, friend of, or other person, including a person described in274     Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), who is in a position to assist [a person] an275     individual who [may be] is at increased risk of experiencing [or who is likely to experience] an276     opiate-related drug overdose event.277          (3)  The provisions of this section and Title 26, Chapter 55, [Emergency Administration278     of] Opiate [Antagonist] Overdose Response Act, do not establish a duty or standard of care in279     the prescribing, dispensing, or administration of an opiate antagonist.280          Section 9.  Section 58-70a-505 is amended to read:281          58-70a-505. Opiate antagonist -- Exclusion from unlawful or unprofessional282     conduct.283          [(1)  Title 26, Chapter 55, Emergency Administration of Opiate Antagonist Act, applies284     to a licensee under this chapter.]285          (1)  As used in this section:286          (a)  "Dispensing" means the same as that term is defined in Section 58-17b-102.287          (b)  "Increased risk" means the same as that term is defined in Section 26-55-102.288          (c)  "Opiate antagonist" means the same as that term is defined in Section 26-55-102.289          (d)  "Opiate-related drug overdose event" means the same as that term is defined in290     Section 26-55-102.291          (e)  "Prescribing" means the same as that term is defined in Section 58-17b-102.292          (2)  The prescribing or dispensing of an opiate antagonist [as defined in Section293     26-55-102] by a licensee under this chapter is not unprofessional or unlawful conduct if the294     licensee prescribed or dispensed the opiate antagonist in a good faith effort to assist:295          (a)  [a person] an individual who is at increased risk of experiencing [or who is likely to296     experience] an opiate-related drug overdose event [as defined in Section 26-55-102]; or297          (b)  a family member of, friend of, or other person, including a person described in298     Subsections 26-55-105(1)(a)(i) through (1)(a)(iv), who is in a position to assist [a person] an299     individual who [may be] is at increased risk of experiencing [or who is likely to experience] an300     opiate-related drug overdose event.301          (3)  The provisions of this section and Title 26, Chapter 55, [Emergency Administration302     of] Opiate [Antagonist] Overdose Response Act, do not establish a duty or standard of care in303     the prescribing, dispensing, or administration of an opiate antagonist.304          Section 10.  Section 63J-1-602.1 is amended to read:305          63J-1-602.1. List of nonlapsing accounts and funds -- General authority and Title306     1 through Title 30.307          (1)  Appropriations made to the Legislature and its committees.308          (2)  The Percent-for-Art Program created in Section 9-6-404.309          (3)  The Martin Luther King, Jr. Civil Rights Support Restricted Account created in310     Section 9-18-102.311          (4)  The LeRay McAllister Critical Land Conservation Program created in Section312     11-38-301.313          (5)  An appropriation made to the Division of Wildlife Resources for the appraisal and314     purchase of lands under the Pelican Management Act, as provided in Section 23-21a-6.315          (6)  Award money under the State Asset Forfeiture Grant Program, as provided under316     Section 24-4-117.317          (7)  Funds collected from the program fund for local health department expenses318     incurred in responding to a local health emergency under Section 26-1-38.319          (8)  Funds collected from the emergency medical services grant program, as provided in320     Section 26-8a-207.321          (9)  The Prostate Cancer Support Restricted Account created in Section 26-21a-303.322          (10)  State funds appropriated for matching federal funds in the Children's Health323     Insurance Program as provided in Section 26-40-108.324          (11)  The Utah Health Care Workforce Financial Assistance Program created in Section325     26-46-102.326          (12)  The primary care grant program created in Section 26-10b-102.327          (13)  The Rural Physician Loan Repayment Program created in Section 26-46a-103.328          (14)  The Opiate Overdose Outreach Pilot Program created in Section 26-55-105.329          Section 11.  Appropriation.330          Under the terms and conditions of Title 63J, Chapter 1, Budgetary Procedures Act, for331     the fiscal year beginning July 1, 2016, and ending June 30, 2017, the following sums of money332     are appropriated from resources not otherwise appropriated, or reduced from amounts333     previously appropriated, out of the funds or amounts indicated.  These sums of money are in334     addition to amounts previously appropriated for fiscal year 2017.335          Item 1.  To Department of Health - Disease Control and Prevention336               From General Fund$500,000337                    Schedule of Programs:338                    Opiate Overdose Outreach Pilot Program          $500,000339          Item 2.  To Department of Health - Disease Control and Prevention340               From General Fund, One-time$500,000341                    Schedule of Programs:342                    Opiate Overdose Outreach Pilot Program          $500,000Legislative Review NoteOffice of Legislative Research and General Counsel

